TUCSON, Ariz., Nov. 6, 2013 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX), an in vitro diagnostics company dedicated to providing solutions for the global challenge of drug resistant organisms and hospital acquired infections, announced today that Mark C. Miller has been appointed to its Board of Directors.
Mr. Miller currently serves as Executive Chairman and director of Stericycle (NASDAQ: SRCL) where he was Chief Executive Officer from 1992 to 2012 and Chairman of the Board of Directors from 2008 to 2012. During his 20 years as CEO, Mark grew Stericycle's revenues from $1.6 million to $1.9 billion, and in 2009 was selected by Morningstar, Inc. as its "CEO of the Year." Prior to joining Stericycle, Mr. Miller served as vice president for the Pacific, Asia and Africa in the international division of Abbott Laboratories, a diversified health care company, which he joined in 1976 and where he held a number of management and marketing positions. Mr. Miller formerly served as a director of Ventana Medical Systems, Inc., a developer and supplier of automated diagnostic systems. He received a B.S. degree in computer science from Purdue University, where he graduated Phi Beta Kappa.
"We are pleased to have Mark join our Board. His leadership, expertise and wisdom were crucial to the tremendous success of Stericycle. We are looking forward to him applying these skills at Accelerate Diagnostics," commented John Patience, Accelerate Diagnostic's Chairman.
ABOUT ACCELERATE DIAGNOSTICS
Accelerate Diagnostics, Inc. (NASDAQ: AXDX) is an in vitro diagnostics company dedicated to providing solutions for the global challenge of drug resistant organisms and hospital acquired infections. We are focused on developing and commercializing innovative instrumentation for the rapid identification and antibiotic susceptibility testing of infectious pathogens. The Company's revolutionary BACcel™ platform utilizes a proprietary culture-free process with both genomic and phenotypic detection technologies that significantly decreases time to result while achieving high sensitivity and specificity.
In addition to the BACcel system development pipeline, Accelerate Diagnostics also owns and licenses its propriety OptiChem® surface coatings technology, which has numerous applications for binding in bio-analytical systems, such as microarrays.
SAFE HARBOR STATEMENT
Certain statements in this news release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements regarding future prospects and developments are based upon current expectations and involve certain risks and uncertainties that could cause actual results and developments to differ materially from the forward-looking statement, including those detailed in the company's filings with the Securities and Exchange Commission. Accelr8 does not undertake an obligation to publicly update or revise any forward-looking statements, whether as a result of new information or future events
SOURCE Accelerate Diagnostics, Inc.